FL is the second most common type of non-Hodgkin lymphoma (NHL). FL typically presents with generalized painless lymphadenopathy. The disease is usually indolent with a favorable prognosis. Most cases of FL show at (14;18) (q32;q21), which leads to an overexpression of BCL2, an anti-apoptotic protein. The WHO (2017) has a pathological grading system (Grade 1, 2, or 3) for FL that depends on the evaluation of centroblasts. FL workup should include history, physical examination, and laboratory studies, and Imaging. The management of FL depends on the disease stage.